Coronary/Structural Heart

Nyra Medical Announces $20 Million Series A Financing for its Transcatheter Heart Valve Repair Technology

Financing co-led by Vensana Capital and a Large, Global Medical Device Company Use of Proceeds to Advance Development of a Novel Catheter-based Solution for Mitral Regurgitation ATLANTA, Nov. 23, 2022 /PRNewswire/ — Nyra Medical, Inc., a medical device company that is developing a novel transcatheter mitral valve repair technology, today announced the […]

Acticor Biotech: World’s First Clinical Trial to Test New Drug Glenzocimab for Heart Attacks

PARIS–(BUSINESS WIRE)–Partnership between the University of Birmingham and Acticor Biotech (Paris:ALACT) will see patients with heart attacks treated with glenzocimab, a promising new class of drug for the first time. A potential new drug to improve the long-term outcomes for heart attack patients will be trialled in the UK. With the signing […]

CARMAT Announces the Resumption of Commercial Implants of its Aeson® Artificial Heart Is Now Effective

PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announced that the resumption of commercial implants of its Aeson® artificial heart is now effective On October […]

CroíValve Reports Successful First in Human Implants of its DUO Tricuspid Coaptation Valve System

DUBLIN, Ireland–(BUSINESS WIRE)–CroíValve has announced the successful First in Human implants of its DUO Tricuspid Coaptation Valve technology for the treatment of Tricuspid Regurgitation as part of its TANDEM I study in Poland. The procedures were performed as part of an ongoing clinical trial at the National Institute of Cardiology, […]

Neovasc Comments on European Heart Journal Publication

VANCOUVER and MINNEAPOLIS, Nov. 18, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that European Heart Journal – Case Reports has published an article titled, “Implantation of the Coronary Sinus Reducer for Refractory Angina due to Coronary Microvascular Dysfunction in the Context of Apical Hypertrophic Cardiomyopathy […]

Cleerly partners with Heartbeat Health in new heart disease detection program

New alliance combines Cleerly’s AI-enabled approach to identifying early signs of heart disease with Heartbeat Health’s nationwide footprint of virtual cardiologists and care NEW YORK–(BUSINESS WIRE)–Cleerly, the company creating a new standard of care for heart disease, and Heartbeat Health, the nation’s largest virtual-first cardiovascular company, today announced a partnership to […]

WiSE® Technology to Feature in Upcoming APHRS Scientific Session

SUNNYVALE, Calif., Nov. 17, 2022 /PRNewswire/ — EBR Systems, Inc. (ASX: “EBR”, “EBR Systems”, or the “Company”), developer of the world’s only wireless cardiac pacing system for heart failure, is pleased to announce that the Company’s WiSE® technology will be featured at the 15th Asia Pacific Heart Rhythm Society (APHRS) Scientific Session in Singapore from the 18th to the 20th of […]

ENDONOVO ANNOUNCES PLAN TO EXPLORE STRATEGIC ALTERNATIVES FOR ITS SOFPULSE® MEDICAL DEVICE ASSETS

Los Angeles, CA, Nov. 17, 2022 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced plans to explore strategic alternatives to maximize the shareholder value potential of its SofPulse® Pulsed Electro Magnetic Frequency (PEMF) proprietary assets. This may include, but is not limited to, discussions with investment bankers, equity fund […]

Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research

Phase 1 results showed that AV-101 was generally well tolerated with significantly reduced systemic exposure compared to oral imatinib in healthy adult participants WALTHAM, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of […]

Impulse Dynamics Announces 100th Implant Milestone in China for CCM® Therapy

Experience Continues to Show CCM Therapy Addresses Clinical Need in Treating Heart Failure MARLTON, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) — Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure, announced the 100th implant in China, signifying the opportunity for its innovative Optimizer® […]